Gene sequence construct for gene therapy of human immunodeficiency virus infection
US-2024352096-A1 · Oct 24, 2024 · US
US9926382B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9926382-B2 |
| Application number | US-201314050815-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 10, 2013 |
| Priority date | Aug 16, 2010 |
| Publication date | Mar 27, 2018 |
| Grant date | Mar 27, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies. The invention provides a mean of producing a fully human bispecific and bivalent antibody that is unaltered in sequence and does not involve the use of linkers or other non-human sequences, as well as antibody mixtures of two monospecific antibodies and one bispecific antibody. The invention also provides the means of efficiently purifying the bispecific antibody.
Opening claim text (preview).
What is claimed is: 1. A method to generate a bispecific antibody carrying a different specificity in each of a first combining site and a second combining site and consisting of two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and second light chains are different, the method comprising: a. Isolating an antibody or antibody fragment region having a specificity determined by a heavy chain variable domain combined with a first Kappa light chain variable domain; b. Isolating an antibody or antibody fragment region having a different specificity determined by the same heavy chain variable domain as the antibody of step a) combined with a second light chain comprising a second Lambda light chain variable domain; c. Co-expressing in a cell: i. a heavy chain polypeptide comprising the common heavy chain variable domain fused to an immunoglobulin heavy chain constant region; ii. a first light chain polypeptide comprising the first Kappa light chain variable domain fused to a Kappa constant region; and iii. a second light chain polypeptide comprising the second Lambda light chain variable domain fused to a Lambda constant region; and d. Recovering the heavy chain polypeptide, the first light chain polypeptide, and the second light chain polypeptide, thereby generating a bispecific antibody carrying a different specificity in each of a first combining site and a second combining site and consisting of two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and second light chains are different, and wherein the first combining site specifically binds to a first antigen and the second combining site specifically binds to a second antigen. 2. The method of claim 1 further comprising the step of (d) Purifying the bispecific antibodies produced in step c) from the monospecific antibodies produced in step c). 3. The method of claim 2 wherein step d) is an affinity chromatography purification step. 4. The method of claim 3 in which the purification step is performed using Kappa constant domain specific, Lambda constant domain specific or both Kappa constant domain specific and Lambda constant domain specific affinity chromatography media. 5. The method of claim 1 in which the step a) and b) are facilitated by the use of antibody libraries having a common heavy chain and diversity confined to the light chain variable domain. 6. The method of claim 5 wherein the antibody library is displayed on filamentous bacteriophage, at the surface of yeast, bacteria or mammalian cells or used for ribosome or other type of in vitro display. 7. A method of preparing a bispecific antibody that specifically binds to a first antigen and a second antigen, wherein the first and second antigens are different, the method comprising: (a) providing a first nucleic acid molecule encoding a first polypeptide comprising a heavy variable chain region of an immunoglobulin polypeptide or fragment thereof that binds the first antigen, coupled to an immunoglobulin constant region; (b) providing a second nucleic acid molecule encoding a second polypeptide comprising a Kappa light chain variable region of the immunoglobulin polypeptide or fragment thereof that binds the first antigen coupled to a Kappa light chain constant region; (c) providing a third nucleic acid molecule encoding a third polypeptide comprising a Lambda light chain variable region of an immunoglobulin polypeptide or fragment thereof that shares the same heavy variable chain region of the immunoglobulin polypeptide or fragment thereof of step (a) and binds the second antigen, coupled to a Lambda light chain constant region; and (d) culturing a host cell comprising the first, second and third nucleic acid molecules under conditions that permit expression of the first, second and third polypeptides thereby generating a bispecific antibody carrying a different specificity in each of a first combining site and a second combining site and consisting of two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and second light chains are different, and wherein the first combining site specifically binds to a first antigen and the second combining site specifically binds to a second antigen. 8. The method of claim 7 , further comprising the step of (e) recovering the bispecific antibody. 9. The method of claim 7 , wherein the bispecific antibody is recovered in a step (e) using an affinity chromatography purification step. 10. The method of claim 9 , wherein the purification step is performed using Kappa constant domain specific, Lambda constant domain specific or both Kappa constant domain specific and Lambda constant domain specific affinity chromatography media. 11. A method to generate an antibody mixture comprising two monospecific antibodies and one bispecific antibody, all having a common heavy chain, the method comprising: a. Isolating an antibody or antibody fragment region having a specificity determined by a heavy chain variable domain combined with a first Kappa light chain variable domain; b. Isolating an antibody or antibody fragment region having a different specificity determined by the same heavy chain variable domain as the antibody of step a) combined with a second Lambda light chain variable domain; c. Co-expressing in a cell: i. a heavy chain polypeptide comprising the common heavy chain variable domain fused to an immunoglobulin heavy chain constant region; ii. a first light chain polypeptide comprising the first Kappa light chain variable domain fused to a Kappa light chain constant domain; and iii. a second light chain polypeptide comprising the second Lambda light chain variable domain fused to a Lambda light chain constant domain; and d. recovering the heavy chain polypeptide, the first light chain polypeptide, and the second light chain polypeptide, thereby generating an antibody mixture comprising two monospecific antibodies and one bispecific antibody, all having a common heavy chain, wherein the bispecific antibody carries a different specificity in each of a first combining site and a second combining site and consists of two copies of a single heavy chain polypeptide and a first light chain and a second light chain, wherein the first and second light chains are different, and wherein the first combining site specifically binds to a first antigen and the second combining site specifically binds to a second antigen. 12. The method of claim 11 further comprising the step of (d) Purifying the antibody mixture produced in step c) from cell culture supernatant.
against receptors for cytokines, lymphokines, interferons · CPC title
specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor · CPC title
multispecific · CPC title
Interferons · CPC title
Single chain antibody (scFv) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.